Virpax Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Virpax Pharmaceuticals, Inc.
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Boehringer Ingelheim's Paola Casarosa explains that when her company partners with academia, it looks for the best way to mine that level of expertise rather than trying to fit the collaboration to a preferred deal model. Plus, our roundup includes three cancer-related deals and one for dry eye disease.
- Controlled Release
- Topical Delivery
- Drug Delivery
- Large Molecule